131results about How to "Reduce apoptosis rate" patented technology

The invention relates to an SFM (serum-free medium) for culturing MSCs (mesenchymal stem cells). Based on volume, the SFM comprises the following components: 10.2 grams per liter of alpha-MEM (alpha-minimum essential medium), 2.4 grams per liter of sodium bicarbonate, 1 to 5 millimoles of L-glutamine, 50 to 300 milligrams per liter of poloxamer 188, 2 to 8 grams per liter of recombinant human albumin, 10 to 20 milligrams per liter of recombinant human transferrin, 2 to 10 milligrams per liter of recombinant human insulin, 1 to 5 millimoles per liter of Hepes, 50 nanomoles of beta-mercaptoethanol, 0.1 to 1 milligram per liter of lipid, 1 to 5 milligrams per liter of trace element, 0.1 to 5 milligrams per liter of glutathione, 0.5 to 5 milligrams per liter of para-aminobenzoic acid, 1 to 50 nanograms per milliliter of hydrocortisone, 20 to 50 milligrams per liter of vitamin PP, 5 to 50 milligrams per liter of vitamin C, 2 to 10mu M of compound shown in a formula I, 5 to 20mu M of compound shown in a formula II, 10 to 20 nanograms per milliliter of progestin, 1 to 10 milligrams per liter of putrescine, 1 to 10 international units per liter of heparin, 1 to 10 nanograms per milliliter of EGF (epidermal growth factor), 1 to 10 nanograms per milliliter of b-FGF (b-fibroblast growth factor), 1 to 10 nanograms per milliliter of HGF (hepatocyte growth factor) and 1 to 10 nanograms per milliliter of VEGF (vascular endothelial growth factor). The SFM for culturing the MSCs is a BPS-SFM which has determinate chemical components and is free of animal-derived substances.

The invention relates to human sDR5-Fc recombinant fusion protein and application of the human sDR5-Fc recombinant fusion protein to preparation of medicine for preventing and treating drug induced liver injury. Through long-time study of the inventor, the protein gene sequence is selected again, and the novel human sDR5-Fc recombinant fusion protein provided by the invention is obtained. Through a great number of experiments, the human sDR5-Fc recombinant fusion protein can obviously reduce the serum transaminase level in various mouse drug induced liver injury models; the liver pathologic damage is reduced; the liver cell apoptosis rate is obviously reduced; the mouse survival ratio is improved. The human sDR5-Fc recombinant fusion protein is used as novel candidate medicine for preventing and treating the drug induced liver injury; the treatment range is wide; targets are specific; the action is special and fast; the curative effect is obvious; the safety is high; great development potential is realized.

The invention discloses a culture medium capable of promoting the division growth of mesenchymal stem cells, which comprises a serum-free basic culture medium and an additive added on the basis of theserum-free basic culture medium, wherein the additive comprises a hibiscus mutabilis extract, seaweed polysaccharide, astragaloside IV, human serum albumin, transferrin, glutamine, platelet-derived factor, epidermal growth factor, fibroblast growth factor, human insulin growth factor and vitamin A; the hibiscus mutabilis extract has antioxidant and cell activating activity, and can effectively promote the growth of cell metabolic by compounding seaweed polysaccharide and astragaloside IV; human serum albumin, transferrin, glutamine and vitamin A provide essential nutrient substances for the growth of stem cells; platelet-derived factor, epidermal growth factor, fibroblast growth factor, human insulin growth factor and other cytokines together promote the rapid growth and proliferation ofstem cells; the culture medium not only can improve the growth activity of mesenchymal stem cells, shorten the culture time, promote the expression of cell growth factors, but also can maintain the stem cell activity of the differentiation potential of mesenchymal stem cells; stem cells are not differentiated in daily culture, thereby providing convenience for scientific research.

The invention discloses an islet cell cryopreservation solution and a using method thereof. The cryopreservation solution is prepared by adding 10-40% of a conditioned medium of mesenchymal stem cells, 10-50% of human blood albumin, 1-10 mM of gamma-aminoethanesulfonic acid, 0.1-10% of dimethyl sulfoxide, 1-20 mM of 4-hydroxyethylpiperazineethanesulfonic acid, 21nM-50uM of SD-28, 1-20 mM of 6-hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid and 0.1-1.0 mM of 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride in a minimal medium. The cryopreservation solution can prolong the cryopreservation time without affecting various functional indexes of islet cells so as to meet the short-term long-distance transportation of the islet cells.

The invention discloses a Chinese medicinal extract for eliminating face red blood streaks and a preparation method and application thereof. The Chinese medicinal extract is extracted from a Chinese medicinal composition which consists of rhubarb, pagoda tree flower bud, astragalus and matricaria chamomilla according to the weight part ratio (30-50):(15-25):(15-25):(5-15). The preparation method comprises the following steps of: smashing the rhubarb, pagoda tree flower bud, astragalus and matricaria chamomilla in the ratio; adding propylene glycol serving as an extracting agent for soaking; performing ultrasonic extraction; cooling; filtering and centrifuging; and performing suction filtration, and extracting supernate to obtain the Chinese medicinal extract. The extraction and separationmethod of the Chinese medicinal extract provided by the invention is simple and convenient, the obtained product has high purity, and the product quality is improved greatly. The used Chinese medicinal composition has the effects of reducing the blood vessel permeability, restoring microcirculation, regulating the immunologic function, promoting skin metabolism, increasing collagen and elastin, and the like, so that the extract of the Chinese medicinal composition can be taken as an additive for eliminating face red blood streaks.

The invention aims at providing a serum-free culture medium for umbilical cord blood mesenchymal stem cells. The serum-free culture medium is composed of a cell factor combination, an alpha-MEM culture solution, insulin, transferring, BMP-4, BOP1, FGF-2 and AMD3100. The cell factor combination comprises IL-3, IL-6, SCF and FL, the concentration of IL-3 is 1-20 ng / ml, the concentration of IL-6 is 1-100 ng / ml, the concentration of SCF is 1-100 ng / ml, and the concentration of FL is 1-100 ng / ml. The serum-free culture medium is developed and researched, the adding sequence of hematopoiesis factors is changed, and the defects of existing umbilical cord blood mesenchymal stem cell culture media in the prior art are overcome.

The invention relates to a construction method of an immortalized telocytes system. The construction method comprises the following steps: (1) digesting shorn off mouse lung tissue block in type-II collagenase, carrying out filtering and centrifuging, collecting cyte precipitate, culturing the cyte precipitate in a culture medium, after fibrocytes are attached to a wall, transferring supernate to another culture dish, culturing for 12 hours, then changing liquid, and continuing culturing for 3-5 days; (2) taking a trace spearhead as a cyte scraper to scrape off the fibrocytes, and after scraping off the fibrocytes repeatedly, observing a specificity structure telopode and identifying telocytes by an immune marker; and (3) taking the telocytes as host cells, infecting the host cells by using a retroviral vector which contains SV-40-large tumor antigen, and carrying out passage, screening and identifying. Even if the immortalized telocytes system is cultured to the 50th generation, the state is still stable, and therefore, the problem that the purity and the stability of the telocytes cannot be guaranteed by repeated separation and extraction in the prior art.

The invention provides an antioxidant peptide in perilla seeds and an application thereof. The sequence of the antioxidant peptide is Tyr-Leu(YL). In vitro experiments show that the polypeptide can effectively remove ABTS, superoxide anions and various reactive oxide species (ORAC). Meanwhile, the peptide can effectively inhibit linoleic acid and rat liver lipid peroxidation. Cell experiments prove that the peptide is safe to cells and has obvious inhibiting effects on oxidative damages of the cell HepG-2. The antioxidant peptide has the characteristics of simple structure, safety, strong antioxidation activity, and the like, can serve as an excellent substitute for existing synthetic antioxidants and has important value for development and application of novel antioxidant health care products and food additives.

The invention discloses a low-serum culture medium for high-density suspension culture of BHK-21 cells and an application of the low-serum culture medium in proliferation of FMDVs (foot and mouth disease viruses). According to researches on the metabolism level and mutual adjustment of nutritional substances such as glucose and the like in the growth process of the BHK-21 cells, the low-serum culture medium for individual BHK-21 cells is provided and comprises an amino acid part, a vitamin part, a balanced salt part and other additive parts. The culture medium is used for high-density suspension culture of the BHK-21 cells, the effective utilization rate of the nutritional substances by the cells can be greatly increased, the concentration of metabolism byproducts is reduced, and accordingly, the cell culture efficiency is improved; besides, the BHK-21 cells cultured by the culture medium have increased sensitivity for different serums of animals suffering from FMDV, the content of effective antigens 146S of the viruses is substantially increased, the purposes of high cell growth efficiency, cell growth controllability and minimization of the concentration of the metabolism byproducts are achieved, the production efficiency of biological products is higher, the production cost is lower, and the low-serum culture medium has remarkable economic benefits.

The invention discloses a DN T cell transformation and multiplication method which comprises the following steps: (1) extracting mononuclear cells in an initial sample, and removing CD8<+>T cells and NK cells from the mononuclear cells; (2) culturing the sample obtained in the step (1) in vitro with a culture medium containing a T cell stimulant and cell factors; adding an OX40 activated antibody or an OX40 ligand at the same time in the culturing process; (3) purifying DN T cells after 5-7 days' culture. The method can be implemented without purifying CD4<+>T cells or natural DN T cells, so that the operation difficulty is reduced, the operation efficiency is improved, and the culture period is short; the apoptosis rate of DN T cells in multiplication can be effectively reduced, and the immunosuppression function can be improved; the DN T cell yield is greatly improved as compared with that in the prior art; the obtained DN T cells have remarkable immunosuppression function, the percentage of the proliferated CD4 T cells is reduced to 2.94% as compared with that in the prior art, and the suppression ratio can reach 93%.

The invention relates to the technical field of a horse placenta extract and a pharmaceutical application thereof, specifically to a horse placenta water-soluble protein extract with bioactivity, a preparation method and an application thereof. According to the present invention, during an extraction process, a phosphate buffer solution with a pH value close to a physiological pH value and an osmotic pressure close to a physiological osmotic pressure is adopted as an extraction solvent so as to maintain activity of active substances in a horse placenta to the maximal degree; with the horse placenta extract, activity of normal lymphocytes can be significantly enhanced, proliferation activity of T-lymphocytes and B-lymphocytes induced by ConA and LPS can be significantly inhibited, and killing activity of NK cells on PC-3 cancer cells can be significantly enhanced, such that adjustment effects are provided for immune functions to a certain degree; and with the horse placenta extract, oxidative damage of skin fibroblasts due to H2O2 can be significantly inhibited, cell viability can be improved, MDA content in cells can be reduced, enzyme activities of SOD and GPx can be improved, apoptosis rate can be reduced, and DNA damage can be inhibited, such that a certain protection effect is provided for oxidative damage.

An application of human s DR5 protein in preparing the medicines for treating the viral hepatitis B, especially the acute severe viral hepatitis B, by protecting liver cells and preventing the wither of liver cells is disclosed.

The invention discloses an improved stem / progenitor cell and regenerative porcine islet cell co-culturing method. The method comprises the following steps: culturing NICCs by using a complete medium for 3d, re-suspending three kinds of cells by using the complete medium according to a cell quantity ratio of NICCs (IEQ): EPCs (P3-P5): MSCs (P3-P5) of 1:8:8-1:12:12, placing in an anchorage-independent culture dish or culture bottle, co-culturing in a 37DEG C thermotank for 8-12h without shaking, transferring the cells into a culture dish or culture bottle with the medium containing area about 6 times the above culture dish or culture bottle, continuously culturing, and replacing a culture solution once every other day. The method has the advantages of increase of the NICC coating efficiency of the MSCs and the EPCs, reduction of the cell apoptosis rate, increase of the cell viability, and improvement of the cell culture yield, and is an improved simple, stable and efficient stem cell and regenerative porcine islet cell co-culturing method.

This invention relates to methods for treating, preventing and / or managing hematopoietic neoplasm in a subject by administering to the subject combretastatin A-4 phosphate, or a pharmaceutically acceptable salt thereof. The method may further comprise co-administering a chemotherapeutic agent.

The invention also discloses a culture medium for increasing the proliferation rate of sub-omnipotent stem cells. The culture medium comprises a DMEM culture medium, and further comprises the following components: 3-3.5 grams per liter of hydroxyethyl starch, 30-38 milligrams per liter of lipoic acid, 0.5-0.6 grams per liter of potassium bicarbonate, 0.3-0.6 micrograms per liter of sodium ethylenediamine tetraacetate, 2-5 micrograms per liter of hyaluronic acid, 5-8 micrograms per liter of taurine, 0.9-1.2 grams per liter of insulin-like growth factor, 0.3-0.6 grams per liter of recombinant human insulin, 15-30 micrograms per liter of placental growth factor, 20-30 milligrams per liter of platelet-derived growth factor, 60-90 milligrams per liter of glutathione, 40-80 milligrams per liter of vitamin and 80-120 milligrams per liter of plant extract.

The invention relates the method for producing renovation pigling Langer-hans' insula cell. The method comprises the following steps: 1 choosing donator: choosing health pigling, at sterility opening abdomen, getting pancreatic, removing integument, vessel, connective tissue in Hank`s liquid at 4Deg.C; 2 separating and purifying Langer-hans' insula cell: separating Langer-hans' insula cell from external secretion tissue with finishing machine, centrifuging with Dextran non-sequence density gradient, getting Langer-hans' insula cell; 3 culturing Langer-hans' insula cell: carrying out CO2 culturing with non-serum microballoon carrier, using RPMI-1640 culture liquid, adding fibrin, packaging the Langer-hans' insula cell in the APA biological film to form microsphere, at 37Deg.C, culturing in the CO2 culture box, changing culture liquid every 48 hours, and getting the product.

The invention relates to the field of biomedicines, in particular to application of zymosan-A or derivative thereof in preparing a medicine for protecting acute radioactive bone marrow injury. The application is characterized in that after proofed by mouse in-vivo experiment, the zymosan-A can obviously reduce the injury degree to a bone marrow hematopoietic system due to ionizing radiation, promote the restoration of the hematopoietic system, and inhibit the decreasing of peripheral blood leucocyte caused by the ionizing radiation; after proofed by in-vitro cytology experiments, the zymosan-A can reduce the cell withering rate after radiation, and improve the cell proliferation ability after radiation; after proofed by TLR2 knocking the mouse, the zymosan-A can play the radiation protecting function after activating a TLR2 signal channel in a targeting way; after proofed by the experiments, the zymosan-A can decrease the radioactive injury of the bone marrow hematopoietic system of the mouse via activating the TLR2 signal channel, and protect the peripheral blood leucocyte, so that a new reference is provided for the zymosan-A protecting the acute radioactive bone marrow injury.

This invention discloses a method for culturing human embryonic stem cells and the special culture medium. The formula of the culture media comprises: N2 5-30mL, B27 10-60mL, glutamine 0.0146-0.73g, beta-mercaptoethanol 5-10uL, one or several non-essential amino acids in total 3-30mL, alkaline desmocyte growth factor 20-200mg, bovine serum albumin 0.2-0.8g, using DMEM / F12 to volume to 1000ml, pH7.2-7.4. The culture meida is characterized of determined ingredients without any elements from animal sources and high fail-safe reliability for application. The culturing method and clutue meidum of this invent can give the culturing of human embryonic stem cells beneficial effects like fast proliferation, low death rate, safety, stability and long generation time. This invention will play important rols in the culturing of human embryonic stem cells to satisfy the needs of clinical and medical research, with a bright prospect of broad application.

The invention discloses a special culture medium and method for culturing porcine trophoderm stem cells. The special culture medium is composed of bFGF, activin A, Y27632, Knockout SR and beta-mercaptoethanol. The culture method comprises the following steps: previously coating a stem cell culture dish with an extracellular matrix; digesting porcine blastula with proteinase to remove the zona pellucida, transferring into the stem cell culture dish, and adding the special culture medium; and culturing until a trophoderm stem cell cloning group with the total cell count of 1000-2000 is formed, digesting into unicells, transferring into a new extracellular-matrix-coated culture dish, and carrying out cell subculture. The special culture medium has the advantages of definite components and high use safety, and avoids the pollution of heterogenous cells. The culture method is simple and efficient, and has the advantages of high cloning formation rate, low apoptosis rate, high proliferation and subculture capacity, high safety and high stability when being used for porcine trophoderm stem cell culture.

The invention discloses a culture medium good in hematopoietic stem cell adherence. The culture medium comprises an RPMI-1640 culture medium, 5-8mug / L of hyaluronic acid, 3.2-3.8g / L of trehalose, 20-30mg / L of ethanolamine, 0.7-1g / L of potassium bicarbonate, 6-9mug / L of methionine chelate selenium, 2-5mug / L of beta-mercaptoethanol, 2-3g / L of transferrin, 200-260mg / L of stem cell factors, 50-80mg / L of placental growth factors, 30-50mg / L of fibroblast growth factors, 80-100mg / L of glutathione, 80-110mg / L of vitamins and 180-220mg / L of plant extracts. The culture medium is good in cell adherence, rapid in proliferation rate, pathogen-resistant microbial action of the cultural medium is improved, components of animal origin are avoided, residues or pollution cannot be caused, and cost of the culture medium is lowered.

The invention relates to the technical field of biomedicine engineering and provides application of a reagent for inhibiting or down-regulating expression of a GTSE1 gene in preparation of a tumor radiotherapy sensitization drug, particularly application in preparation of a lung cancer radiotherapy sensitization drug. Experiments prove that GTSE1 knockdown promotes DNA damage of exposure to lung cancer cells, increases the radiosensitivity of three lung censer cells significantly and increases the apoptosis rate of the three lung cancer cells after exposure significantly with the increase of an exposure dose, and the cell survival rate of the three lung cancer cells is obviously lower than that of a normal lung cancer cell group. Therefore, the application provides a new exploration for improving the sensitivity of radiotherapy, contributes to radiotherapy sensitivity of malignant tumor and has certain clinical application prospects.

The invention discloses a cryopreservation and resuscitation method, cryopreservation liquid and resuscitation liquid for pig islet cells. According to the method, before cryopreservation, sodium alginate is used to wrap the pig islet cells, a relatively-stable three-dimensional adhesion space is formed without having impact on normal metabolic level, and stable recycling rate (higher than 60%) and insulin secretion function are ensured after cryopreservation and resuscitation of the pig islet cells to achieve the objective of building an islet cell bank.

The invention discloses an application of oxymatrine in medicines for treating neonatal hypoxic ischemic brain damages. An experiment result shows that oxymatrine has a certain dose-effect correlation when used in a safe dose range; when the dose is 120mg / kg of body weight, the volume of ischemia area cerebral infarction and neuron apoptosis rate can be reduced; pathological damages to brain tissues can be relieved; the activity of antioxidase in the brain tissues can be improved; and the content of malondialdehyde is lowered. The oxymatrine has the effects of preventing injuries and deaths caused by neonatal hypoxic ischemic brain damages and promoting neural functional recovery.

The present invention discloses pharmaceutical use of Echinacoside (ECH) for treatment of hypoxic-ischemic encephalopathy. The experimental results of the present invention indicate that the Etoposideat a dose of 160 mg / kg can significantly improve cerebral infarction volume and neuronal damage and apoptosis in a hypoxic-ischemic model of neonatal rats when used in a safe dose range, and prove that the Etoposide can promote the recovery of neuronal ischemia and hypoxia injury and prevent disability and death after hypoxic ischemic encephalopathy.

The invention discloses application of a CTNNB1 gene in porcine ovarian granulosa cells, and belongs to the technical field of cell engineering and gene engineering. According to the invention, the relative expression quantity of CTNNB1 mRNA in ovarian tissues, follicles with different sizes and granulosa cells of pigs in different periods, and the proliferation and apoptosis of the granulosa cells after overexpression and inhibition of CTNNB1 and the secretion of steroid hormones are detected. Results show that the CTNNB1 gene participates in promoting the proliferation of granulosa cells andthe secretion of estradiol and inhibiting the apoptosis of granulosa cells and the secretion of testosterone and progesterone, which indicates that the CTNNB1 gene participates in the development andmaturation of ovarian follicles of sows. Materials are accumulated for molecular mechanism research in the sow ovarian follicle development process.

The invention discloses application of a berberine and doxorubicine mixed preparation in preparation of a medicament against doxorubicine cardiac dysfunction or tumor. The molar concentration ratio of the berberine to the doxorubicine in the medicament is (0.625-4): 1, and the optimal ratio is 1:1. The medicament is an oral preparation or an injection preparation. The combined use of the berberine and the doxorubicine can lighten myocardial damage caused by the doxorubicine, also can play a role in inhibiting myocardial apoptosis caused by the doxorubicine, and does not weaken, even enhance the anti-tumor effect of the doxorubicine at the same time.

The invention discloses a medium for umbilical cord MSCs (mesenchymal stem cells). The medium is prepared from the following components: a basal medium, human serum albumin, myricetin, panax notoginsenoside, emodin, linoleic acid, trypsin, aprotinin, lumican, basic fibroblast growth factors, folic acid, beta-mercaptoethanol, astragalus polysaccharides, transferrin, vitamins and amino acid. The medium is compounded from the basal medium, human serum albumin, myricetin, panax notoginsenoside, emodin, linoleic acid, trypsin, aprotinin, photoprotective glycoprotein, the basic fibroblast growth factors, folic acid, beta-mercaptoethanol, astragalus polysaccharides, transferrin, the vitamins and the amino acid, the components play a synergistic role, and accordingly, the umbilical cord MSCs can be successfully cultured, proliferation of the umbilical cord MSCs is promoted, the growth rate of the umbilical cord MSCs is increased, activity of the umbilical cord MSCs during in-vitro proliferation and differentiation is improved, and the apoptosis rate is decreased.

The invention discloses a medicine compound for treating myocardial ischemia reperfusion of a rat, belonging to the technical field of the medicine compound for preventing and controlling myocardial infarction. The medicine compound for treating myocardial ischemia reperfusion of the rat comprises the following ingredients: 5-15 parts of astragalus extract, 5-10 parts of salvia miltiorrhiza, 2-5 parts of carthamus tinctorius, 1-3 parts of rhodiola rosea, 0.25-0.75 part of procyanidine, 0.25-0.75 part of adiponectin and 1-2 parts of puerarin. According to the medicine compound for treating myocardial ischemia reperfusion of the rat and an application method thereof provided by the invention, the myocardial ischemia reperfusion injury can be obviously relieved; procyanidine which has the effect of relieving inflammation and oxidative stress is added into the medicine compound, so that the oxidation resistance of a body can be promoted; adiponectin has the functions of regulating glucolipid metabolism, resisting inflammation and resisting atherosclerosis; the medicine compound has the function of protecting rat myocardium; the medicine compound can greatly reduce the apoptosis rate of the cells and protect the complete form of the cells.

The invention discloses an application of cornflower-3-O-galactoside in preparing foods or medicines for improving cognitive functions of old people. Results from animal experiments show that: compared with a control group (mice are fed with distilled water), the step-through latencies of animals fed with the cornflower-3-O-galactoside are all evidently prolonged; the escape latencies of mice in Morris water maze are evidently shortened; the duration time on a platform quadrant is evidently prolonged, and times of crossing the platform are evidently increased. The hint shows that the spatial memory ability of the old-aged mice compensated with the cornflower-3-O-galactoside can be evidently improved. Compared with an H2O2 model group, the LDH activity of hippocampal nerve cell supernate inthe group fed with the cornflower-3-O-galactoside evidently decreases and the nerve cells apoptosis rate evidently decreases. The hint shows that the cornflower-3-O-galactoside can evidently suppressthe hippocampal nerve cell apoptosis induced by H2O2 and play a protection role in the hippocampal nerve cells damaged by H2O2.

The invention provides a stem cell preparation for treating diabetes mellitus and a preparation method of the preparation. The stem cell preparation consists of bone marrow pluripotent stem cells, bone marrow pluripotent stem cell source islet-like cells and adipose-derived stem cells which are evenly mixed in normal saline in a ratio of 1:1:1. The cells adopted by the stem cell preparation have the multiple differentiation potential and the high proliferation characteristic and are abundant in source, convenient and easy to take and small in damage to organisms, in vitro separation, culture and induction operations can be conducted easily, abundant cell sources can be provided for treatment of the diabetes mellitus through the cells, and the preparation can be clinically used on a large scale. The stem cell preparation is free of immunological rejection when being implanted into a body. A specific induction culture system is used in the preparation method of the stem cell preparation, and the bone marrow pluripotent stem cells are directionally differentiated into the islet-like cells in vitro, so that the problem that cells implanted under the continuous high blood glucose condition of the diabetes mellitus are difficult to differentiate into cells capable of secreting insulin is solved.